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430a Tuesday, February 10, 2015the pocket for their contribution to DGB1 to understand the interactome network
at the three binding sites. It is possible that the different sensitivities of the fetal
a-g site vs. the adult a-ε and a-d sites to ACh and choline are important for the
proper maturation and function of the neuromuscular synapse.
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Acetylcholinesterase inhibitors (AChEI) and the N-methyl-D-aspartate
(NMDA) receptor antagonist memantine are among the few FDA-approved
drugs for Alzheimer’s disease. In effort to develop multi-target (AChE-
NMDA)-directed ligands for the treatment of Alzheimer’s disease, a series 7-
Methoxytacrine-Adamantylamine thiourea heterodimers have been synthesized
and evaluated for their effects as AChEI (Spilovska et. al. 2013, Molecules 18,
2397-2418). In this report, we extend their pharmacological characterization
by examining their effects on neuronal and muscle-type nicotinic acetylcholine
receptors (nAChR) and muscarinic acetylcholine receptors (mAChR). We also
compare their pharmacology to 7-Methoxytacrine-Adamantylamine urea heter-
odimers. 7-Methoxytacrine-Adamantylamine thiourea derivatives containing
2-8 carbon linkers inhibited AChE and butyrylcholinesterase (BChE) with
high potency (IC50, 0.5-6 mM), whereas 7-Methoxytacrine-Adamantylamine
urea derivatives inhibited AChE with higher potency than BChE. None of the
tested compoundpotentiatedM1mAChRor nAChRs responses. They havemin-
imal effects on acetylcholine-induced currents in Xenopus oocytes expressing
neuronal a4b2 nAChR and inhibited M1 mAChR at higher concentrations
(IC50s>10 mM). At concentration that inhibit AChE, both thiourea and urea de-
rivatives inhibited acetylcholine-induced currents in Xenopus oocytes express-
ing muscle-type AChRs. Our preliminary results also suggest that the length
of the carbon linker affect 7-Methoxytacrine-Adamantylamine urea interactions
with AChRs, and further modifications of their structure are expected to yield
compounds with more favorable pharmacological profiles.
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Muscle-type nicotinic acetylcholine receptors (nAChRs) mediate fast synaptic
cholinergic responses at neuromuscular junctions. The adult subtype of the re-
ceptor is composed of a1, b1, d, and ε subunits in the ratio 2:1:1:1. Although
nicotine is the name-giving agonist for ionotropic acetylcholine receptors, only
a few studies investigated its effect of nicotine on this specific nAChR subtype.
A comprehensive knowledge of the mechanism underlying the nicotine-
induced gating is still missing.
For this reason, we had a closer look to macroscopic (a1)2b1dε receptor cur-
rents evoked by fast nicotine jumps and compared them with acetylcholine-
evoked responses. The receptors were heterologously expressed in HEK293
cells. After lifting and positioning the cells in front of a piezo-driven double-
barreled application pipette, whole-cell currents were monitored.
Herein, nicotine was found to be an agonist with a relative potency of about
0.60 compared to the full agonist acetylcholine. The efficiency was about
30 times lower than for acetylcholine (EC50 ¼ 97.0 mM versus EC50 ¼
3.35 mM). When activated by nicotine, (a1)2b1dε receptors desensitize slower
than receptors activated by acetylcholine. As expected from single-channel
analysis (Akk and Auerbach, Br J Pharmacol. 128:1467-76, 1999; Jadey
et al., J Gen Physiol. 141:95-104, 2013), off-currents, occurring after removal
of high nicotine concentrations, confirmed the idea of nicotine acting as a chan-
nel blocker at concentrations higher than 1 mM.
In summary, the data provide new insight into the nicotine-induced gating of
adult muscle-type receptors. The differences in comparison to the physiological
ligand acetylcholine and the action of nicotine as a partial agonist are discussed.
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We are examining the M3 transmembrane helix of mouse muscle AChRs with
regard to C4O gating and the effects of positive allosteric modulators
(PAMs). The relative ground and transition state gating energies were estimatedfrom single-channel currents of AChRs havingM3mutations.Diliganded gating
rate and equilibrium constants were measured for ~100 mutations in 5 subunits
(a, b, d, ε and g; 20 mM choline or 500 mMACh,100mV, HEK cells). In gen-
eral: i) the effects of themutationswere small (%1 kcal/mol), ii) the effects were
similar among subunits, iii) the mutations in different subunits were indepen-
dent, iv) the mutations have no effect on the energy from the agonist affinity
change (%~0.3 kcal/mol) and v) most phi values were low (~0.3). Crystal struc-
tures ofAChRhomologues in detergents suggest that the low phi positions inM3
are interaction sites for PAMs. We investigated the actions of PNU-120596 and
IVM(1-1000nM). InWTAChRs (adult and fetal) these ligands increase substan-
tially the frequency and lifetime of constitutive openings in a manner consistent
with action at a low-phi position such as in M3. Such potentiation was also
apparent at low [agonist] (<1mMACh or choline), but at higher [agonist] gating
kinetics became complex and the potentiation was less clear. The PAMs also
increased substantially the frequency and lifetime of constitutive openings in
some of the M3 mutants (to W).
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Many ion channels exhibit multiple patterns of kinetic activity (‘modes’) in
single-channel currents. This behavior is rare in WT mouse muscle acetylcho-
line receptors (AChRs), where A2C4A2O gating events are well-described by
single exponentials. We have found that mutations of all loop C residues at the
transmitter binding site (except aY190 and aY198) increase the probability of
modes. The free energy of diliganded gating is the sum of that for unliganded
gating and from agonist affinity-changes at 2 binding sites: DG2¼DG0þ2DGB.
For WT adult AChRs these values are (100 mV; kcal/mol): 1.9, þ8.3 and
5.1 (ACh). All mutations of aP197 (ACDEGIKSVY) had at least 2 gating
modes with all agonists (ACh, Cho, CCh and TMA). We focused on
aP197A and ACh and Cho. There were 3 distinct modes at saturating [agonist]
but only 1 mode without agonist. Hence, the kinetic heterogeneity for this
construct is generated by fluctuations in DGB. DDGB was estimated for each
mode (kcal/mol) for ACh (1.7, WT and þ1.6) and Cho (2.2, WT and
þ0.9). That is, the gating equilibrium constant for one mode was ~30-times
larger than the WT (for both agonists), for another was about the same as the
WT and for the third was ~8-times smaller. An added F mutation at aY190
or aW149 reduced modal gating whereas one at aY198 or aY93 did not. An
F substitution at εW55 had no effect, but one at dW57 reduced the modes.
We also examined AChRs having only 1 active binding site and observed
less heterogeneity from aP197A at the fetal a-g site vs. the adult a-ε or a-d
sites. Our working hypothesis is that mutations in loop C allow the agonist
to sample multiple, meta-stable positions within the binding pocket, to produce
distinct DGB values.
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Desformylflustrabromine (dFBr) potentiates 4b2 nAChR in vitro (Kim
et al. 2007, Biorg. Med. Chem. Lett. 17: 4855) and reduces nicotine self-
administration in vivo (Liu 2013; Psychopharmacology 230: 203). We have
reported that dFBr is a potent inhibitor (IC50, ~1 M) of human (Ha12b1εd) and
Torpedo (Ta12b1gd) muscle-type nAChRs. We also found, using [
3H]dFBr
reversible binding and dFBr displacement of [3H]PCP binding, that dFBr binds
with high affinity to the muscle-type nAChRs ion channel in the desensitized
state. But, when we photolabeled nAChR-rich Torpedo membranes with [3H]
dFBr in the presence of agonist, four dFBr binding sites were evident. [3H]
dFBr photolabeled amino acids in the ion channel and in three binding siteswithin
the extracellular domain previously identified for nAChRs PAMs galanthamine
andphysostigmine.The high affinity binding of dFBr in the ion channel precludes
the ability to study the functional contribution of dFBr binding within the extra-
cellular domain and to determine whether dFBr acts as inhibitor or potentiator at
these sites. Therefore, we are introducing mutations in the muscle-type nAChR
ion channel M2 helices to eliminate the channel blocking effect of dFBr. The ef-
fect of M2 mutations on the EC50 of ACh and on dFBr inhibition of muscle-type
nAChRwere examined using two-electrode voltage clamp recording. Serine sub-
stitutions of the leucine at M2-9 of each nAChR subunit decreased dFBr IC50
compared with wild-type, consistent with an open channel blocking mechanism.
This results confirm our [3H]dFBr the photolabeling results demonstrating that
